Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 186

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Neuroendocrine carcinoma of the skin+4

Not recruiting

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BT-001
  • Sponsor:Transgene

Chronic lymphocytic leukaemia

Not recruiting

Study on the Effectiveness of Venetoclax and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Polish Adult Leukemia Group

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Carfilzomib, and Dexamethasone with Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Polish Myeloma Consortium

Non-small cell lung cancer

Not recruiting

Study of Durvalumab and Chemo-Immunotherapy for Patients with Stage III Unresectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione IRCCS Policlinico San Matteo

Plasma cell myeloma

Not recruiting

Study on Daratumumab for Multiple Myeloma Patients with Minimal Residual Disease Reappearance or Biochemical Relapse

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Polish Myeloma Consortium

Plasma cell myeloma

Not recruiting

Study of belantamab mafodotin with drug combination for newly diagnosed multiple myeloma patients who cannot receive transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Hellenic Society Of Hematology

Squamous cell carcinoma of the oral cavity+9

Not recruiting

Study of low-dose radiation therapy combined with paclitaxel and carboplatin in patients with advanced throat and larynx cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Chronic myeloid leukaemia

Not recruiting

Study on the Effectiveness and Safety of Ropeginterferon and Bosutinib for Patients with Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:St. Olavs Hospital HF

Rectal cancer

Not recruiting

Study on Valproic Acid with Bevacizumab and Oxaliplatin/Fluoropyrimidine for Patients with RAS-Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Hepatocellular carcinoma

Not recruiting

Study on Fecal Microbiota Transplant with Atezolizumab and Bevacizumab for Liver Cancer Patients Unresponsive to Previous Immunotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Medical University Of Vienna

Chronic lymphocytic leukaemia+1

Not recruiting

Study of TL-895 and Navtemadlin for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:1-4-{[6-Amino-5-(4-Phenoxy-Phenyl)-Pyrimidin-4-Ylamino]-Methyl}-4-Fluoro-Piperidin-1-Yl)-Propenone
  • Sponsor:Telios Pharma Inc.

Title: Evaluation of 68Ga-PSMA-11 PET/MRI and PET/CT Imaging for Treatment Planning in Patients with Intermediate and High-Risk Prostate Cancer

Not recruiting
InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:PSMA-11
  • Sponsor:Agencja Badań Medycznych

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.